Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 31Endocrine 13Thoracic 12NET 9Sarcoma 6Head & Neck 5Other solid neoplasm 3Gynecologic 3Tumor-Agnostic 2Breast 2Lymphoid 1

Conditions

Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Osteosarcoma 1Lymphoma 1

Interventions

Rituximab 1371Cyclophosphamide 1296Vincristine 662Doxorubicin 583Etoposide 525Prednisone 504Cytarabine 481fludarabine 461Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 254ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 227Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × surufatinib × Lymphoid × Clear all
NCT05093322 2024-06-07

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Hutchmed

Phase 1/2 Completed
13 enrolled 17 charts
LymphoidSarcoma

Lymphoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡